New hope for Hard-to-Treat leukemia? early trial launches
NCT ID NCT06366789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new oral drug, ZE46-0134, in 150 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. The study focuses on people with specific gene changes (FLT3 or spliceosome mutations). The main goals are to check safety, find the right dose, and get a first look at whether the drug can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZE46-0134 (oral capsules)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat AML who have specific gene mutations.
- What could go wrong
- This is a very early Phase 1 trial with only 150 participants, so it may not show clear benefit or could have unexpected side effects. Many early-stage drugs do not advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML WITH GENE MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
NOT_YET_RECRUITINGTaichung, 404327, Taiwan
-
Eastern Health - Box Hill Hospital
RECRUITINGMelbourne, Victoria, 3128, Australia
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Gachon University Gil Medical Center
NOT_YET_RECRUITINGIncheon, Gyeonggi-do, 21565, South Korea
-
Korea University Anam Hospital
NOT_YET_RECRUITINGSeoul, 02841, South Korea
-
Linear Clinical Research Ltd
RECRUITINGPerth, Western Australia, 6009, Australia
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
National Cheng Kung University Hospital
NOT_YET_RECRUITINGTainan, 704302, Taiwan
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, 03080, South Korea
-
Taichung Veterans General Hospital
NOT_YET_RECRUITINGXitun, 407219, Taiwan
-
Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare
NOT_YET_RECRUITINGNew Taipei City, 235041, Taiwan
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
-
The Catholic University of Korea Seoul St. Mary's Hospital
NOT_YET_RECRUITINGSeoul, 06591, South Korea
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
-
The University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45219, United States
-
University of Kansas
RECRUITINGLawrence, Kansas, 66160, United States
-
University of Maryland
RECRUITINGCollege Park, Maryland, 20742, United States
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.